Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri - a podcast by Pharma Talk Radio

Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance.
Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins University

Learn more about the IO360° Summit at www.io360summit.com

Further episodes of PharmaTalkRadio

Further podcasts by Pharma Talk Radio

Website of Pharma Talk Radio